Brokerages expect that Neos Therapeutics Inc (NASDAQ:NEOS) will post earnings of ($0.60) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Neos Therapeutics’ earnings, with estimates ranging from ($0.67) to ($0.53). Neos Therapeutics reported earnings per share of ($1.14) during the same quarter last year, which suggests a positive year over year growth rate of 47.4%. The company is scheduled to announce its next quarterly earnings report on Tuesday, March 13th.

According to Zacks, analysts expect that Neos Therapeutics will report full year earnings of ($2.87) per share for the current financial year, with EPS estimates ranging from ($2.95) to ($2.73). For the next year, analysts anticipate that the business will post earnings of ($1.59) per share, with EPS estimates ranging from ($1.90) to ($1.34). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Neos Therapeutics.

Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Wednesday, November 8th. The company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.22. The firm had revenue of $6.70 million for the quarter. Neos Therapeutics had a negative net margin of 339.52% and a negative return on equity of 551.26%.

NEOS has been the topic of several recent analyst reports. Cowen reiterated a “buy” rating on shares of Neos Therapeutics in a research note on Thursday, October 26th. Cantor Fitzgerald set a $20.00 price target on shares of Neos Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 26th. Wells Fargo & Co set a $14.00 price target on shares of Neos Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 18th. Zacks Investment Research upgraded shares of Neos Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a research note on Wednesday, October 18th. Finally, BidaskClub upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $14.00.

Shares of Neos Therapeutics (NEOS) traded up $0.05 during trading on Wednesday, reaching $10.45. 404,484 shares of the company’s stock traded hands, compared to its average volume of 422,250. The stock has a market capitalization of $302.29 and a price-to-earnings ratio of -3.06. Neos Therapeutics has a one year low of $4.85 and a one year high of $13.15. The company has a debt-to-equity ratio of 4.01, a current ratio of 2.42 and a quick ratio of 2.14.

A number of institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its position in shares of Neos Therapeutics by 167.9% during the second quarter. Russell Investments Group Ltd. now owns 270,020 shares of the company’s stock worth $1,971,000 after acquiring an additional 169,237 shares during the last quarter. Essex Investment Management Co. LLC grew its position in shares of Neos Therapeutics by 24.2% during the third quarter. Essex Investment Management Co. LLC now owns 238,152 shares of the company’s stock worth $2,179,000 after acquiring an additional 46,423 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of Neos Therapeutics by 103.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 43,700 shares of the company’s stock worth $320,000 after acquiring an additional 22,200 shares during the last quarter. Northern Trust Corp grew its position in shares of Neos Therapeutics by 20.9% during the second quarter. Northern Trust Corp now owns 201,266 shares of the company’s stock worth $1,470,000 after acquiring an additional 34,767 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Neos Therapeutics during the third quarter worth approximately $617,000. Institutional investors own 45.75% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “-$0.60 Earnings Per Share Expected for Neos Therapeutics Inc (NEOS) This Quarter” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/03/0-60-earnings-per-share-expected-for-neos-therapeutics-inc-neos-this-quarter.html.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.